Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tighter Legal Provisions Will Deter Spurious Drugs In India But May Be Misused Too, Legal Experts Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Offenses wouldn't require an arrest warrant or allow bail, and small generics companies fear the law will be misused by "vested interests."

You may also be interested in...



Spurious Drugs Issue: Indian Government Proposes Cash Rewards For Informers; Industry Supportive

NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices

U.S. Urges India To Impose Strict Laws Against Counterfeit Drugs

MUMBAI - The Office of the United States Trade Representative has taken a strong stand against counterfeit drugs in India, placing the country on the USTR priority watch list and calling for better and effective systems to check counterfeit drugs

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel